Bioprinting for Drug Development and Testing

Bioprinting is an emerging technology that offers transformative potential in the field of drug discovery and development. By enabling the precise fabrication of complex biological structures using cells, biomaterials, and bioactive molecules, bioprinting bridges the gap between conventional in vitro methods and physiologically relevant models. This chapter explores how bioprinting can address key limitations in current drug development pipelines, such as poor predictive accuracy of animal models and high attrition rates in clinical trials. It highlights the use of bioprinted tissues and organoids as advanced platforms for high-throughput drug screening, toxicity testing, and disease modeling. The integration of patient-specific cells further supports personalized medicine approaches, allowing for customized treatment strategies and reduced adverse drug reactions. Advances in bioinks, printer resolution, and tissue maturation techniques are pushing the boundaries of what is scientifically achievable. Furthermore, the chapter discusses the regulatory landscape and commercialization challenges that need to be overcome to translate bioprinting technologies from bench to bedside. As bioprinting continues to evolve, its role in accelerating drug discovery while improving safety and efficacy metrics appears increasingly critical. The convergence of biotechnology, materials science, and engineering promises a new frontier in developing more accurate, ethical, and efficient therapeutic solutions.